SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Office of National Statistics. Registrations of Cancer Diagnosed in 2002; Cancer Statistics Registrations. England: Office of National Statistics, 2005
  • 2
    Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 84352
  • 3
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 253040
  • 4
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 40817
  • 5
    Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (Bay 43–9006) in patients with advanced renal cell carcinoma (RCC). Proceedings of the Am Soc Clin Oncol 2005: 23, Abstract 4510
  • 6
    Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 251624
  • 7
    Tsui KH, Shvarts O, Smith RB, Figlin RA, DeKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 10905
  • 8
    Sobin LH. TNM sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21: 1922
  • 9
    Patard JJ, Shvarts O, Lam JS et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171: 21815
  • 10
    Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004; 171: 106670
  • 11
    Timsit MO, Bazin JP, Thiounn N et al. Prospective study of safety margins in partial nephrectomy: intraoperative assessment and contribution of frozen section analysis. Urology 2006; 67: 9236
  • 12
    Castilla EA, Liou LS, Abrahams NA et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 2002; 60: 9937
  • 13
    Han KR, Bui MH, Pantuck AJ et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003; 169: 899904
  • 14
    Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004; 171: 58891
  • 15
    Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004; 171: 598601
  • 16
    Leibovich BC, Cheville JC, Lohse CM et al. Cancer specific survival for patients with pT3 renal cell carcinoma – can the 2002 primary tumor classification be improved? J Urol 2005; 173: 7169
  • 17
    Ficarra V, Novara G, Iafrate M et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3–4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 2007; 51: 72231
  • 18
    Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97: 29953002
  • 19
    Fuhrman SA, Lasky LC, Limas A. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 65563
  • 20
    Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173: 185362
  • 21
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 61224
  • 22
    Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 276371
  • 23
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395400
  • 24
    Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 73103
  • 25
    Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 637
  • 26
    Bensalah K, Leray E, Fergelot P et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175: 85963
  • 27
    Atzpodien J, Royston P, Wandert T, Reitz M; DGCIN – German Cooperative Renal Carcinoma Chemo-Immunotherapy Trails Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 34853
  • 28
    Donskov F, Von Der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 19972005
  • 29
    Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174: 175963
  • 30
    Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 192835
  • 31
    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 28996
  • 32
    Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 455966
  • 33
    Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22: 331622
  • 34
    Bou Merhi GF, Mekhail T, Abou Jawde R et al. Prognostic factors for survival in previously treated patient with metastatic renal cell cancer (RCC). Proceedings of the Am Soc Clin Oncol 2003 22, Abstract 1647
  • 35
    Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 45463
  • 36
    Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; 66 (Suppl.): 19
  • 37
    Ivanov S, Liao SY, Ivanova A et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 90519
  • 38
    Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 80211
  • 39
    Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 371421
  • 40
    Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005; 173: 1496501